Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
The addition of Jaypirca to a fixed-duration regimen with venetoclax and rituximab improved PFS by 45.3% in previously treated CLL.
Angus Liu
Jun 15, 2026 8:25am
EHA: J&J chalks up early-stage myeloma win for Talvey/Darzalex combo
Jun 13, 2026 6:00am
Why MRD is becoming central to oncology drug development
Brought to you by
Myriad Genetics, Inc.
The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground
Jun 12, 2026 2:30pm
Precision oncology’s next challenge is translation
Brought to you by
Thermo Fisher Scientific
Amgen to file 3rd-party review of Tavneos data for FDA hearing
Jun 12, 2026 11:12am
